Methadone Hydrochloride Molteni

Methadone hydrochloride, the active ingredient in Methadone Hydrochloride Molteni, is a synthetic opioid presented as an oral formulation for oral use. It is employed in the management of opioid dependence and in the treatment of chronic pain in adult patients, and is marketed in the European Union under strict regulatory standards.

GNH USA supplies Methadone Hydrochloride Molteni as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing and regulatory documentation for global procurement and ensuring timely delivery.

Methadone hydrochloride acts on the opioid system to address dependence and pain conditions. - Opioid dependence: reduces withdrawal symptoms and cravings, facilitating maintenance therapy. - Chronic pain: provides long‑acting analgesia for persistent moderate to severe pain. - Opioid substitution therapy: maintains stable opioid plasma levels to prevent relapse.

Methadone hydrochloride may cause a range of adverse reactions.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Constipation: reduced bowel motility. - Sweating: increased perspiration, especially at night. - Drowsiness: feeling unusually sleepy or fatigued.

Serious or Rare Side Effects: - Respiratory depression: slowed breathing that can be life‑threatening. - QT interval prolongation: risk of cardiac arrhythmias. - Severe hypotension: marked drop in blood pressure.

When prescribing methadone, clinicians should consider several safety measures. - Assess cardiac risk: evaluate QT interval before initiating therapy. - Monitor respiratory function: especially during dose titration and in patients with pulmonary disease. - Avoid abrupt discontinuation: taper under medical supervision to prevent withdrawal. - Use caution in hepatic impairment: adjust dose as needed due to altered metabolism. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Methadone interacts with several drug classes that may alter its safety or efficacy.

Major Interactions (Avoid): - Concomitant CNS depressants: risk of profound respiratory depression. - QT‑prolonging agents: increased risk of cardiac arrhythmia. - MAO inhibitors: may precipitate severe hypotension.

Moderate Interactions (Monitor Closely): - Anticholinergics: may worsen constipation. - CYP3A4 inhibitors (e.g., ketoconazole): increase methadone plasma levels. - CYP3A4 inducers (e.g., rifampin): reduce methadone efficacy.